Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)

    • 21:00 - 23:59
    • 8/06/2022
    • Location: On-Demand
    • Not for CME Credit
    • Type: Workshop
    • Track: N/A
    • +

      WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

      22:50 - 23:00  |  Presenter: Yun Fan

      • Abstract

      This abstract is currently under embargo and will be released during the conference.

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-014 - Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303

      Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      EP08.01-032 - Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study

      Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      EP08.01-033 - ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC

      Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      EP08.01-042 - NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC

      Presenter: Ying Cheng

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-029 - Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

      Presenter: James Chih-Hsin Yang

      • Abstract

      Loading...

    • +

      EP08.02-051 - High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC

      Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      EP08.02-052 - Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC

      Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      EP08.02-078 - Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)

      Presenter: Ying Cheng

      • Abstract

      Loading...

    • +

      EP08.02-092 - Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib

      Presenter: Na Li

      • Abstract

      Loading...

  • +

    PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)

    • 08:30 - 10:20
    • 8/08/2022
    • Location: Hall C1
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N/A
    • +

      PL03.09 - IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

      Presenter: ENRIQUETA FELIP

      • Abstract

      Loading...

  • +

    MA13 - Update on ROS1 Inhibitors and New Pathways

    • 12:00 - 13:00
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

      12:07 - 12:12  |  Presenter: Yun Fan

      • Abstract

      Loading...